11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Synthesis of the heparin-based anticoagulant drug fondaparinux.

      Angewandte Chemie (International Ed. in English)

      Read this article at

      ScienceOpenPublisherPubMed
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Fondaparinux, a synthetic pentasaccharide based on the heparin antithrombin-binding domain, is an approved clinical anticoagulant. Although it is a better and safer alternative to pharmaceutical heparins in many cases, its high cost, which results from the difficult and tedious synthesis, is a deterrent for its widespread use. The chemical synthesis of fondaparinux was achieved in an efficient and concise manner from commercially available D-glucosamine, diacetone α-D-glucose, and penta-O-acetyl-D-glucose. The method involves suitably functionalized building blocks that are readily accessible and employs shared intermediates and a series of one-pot reactions that considerably reduce the synthetic effort and improve the yield. © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

          Related collections

          Most cited references36

          • Record: found
          • Abstract: not found
          • Article: not found

          Heparin-Protein Interactions

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            2003 Claude S. Hudson Award address in carbohydrate chemistry. Heparin: structure and activity.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Chemoenzymatic synthesis of homogeneous ultralow molecular weight heparins.

              Ultralow molecular weight (ULMW) heparins are sulfated glycans that are clinically used to treat thrombotic disorders. ULMW heparins range from 1500 to 3000 daltons, corresponding from 5 to 10 saccharide units. The commercial drug Arixtra (fondaparinux sodium) is a structurally homogeneous ULMW heparin pentasaccharide that is synthesized through a lengthy chemical process. Here, we report 10- and 12-step chemoenzymatic syntheses of two structurally homogeneous ULMW heparins (MW = 1778.5 and 1816.5) in 45 and 37% overall yield, respectively, starting from a simple disaccharide. These ULMW heparins display excellent in vitro anticoagulant activity and comparable pharmacokinetic properties to Arixtra, as demonstrated in a rabbit model. The chemoenzymatic approach is scalable and shows promise for a more efficient route to synthesize this important class of medicinal agent.
                Bookmark

                Author and article information

                Journal
                25044485
                10.1002/anie.201404154

                Comments

                Comment on this article